Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance
Reference number: TA192
Published: 28 July 2010

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - Liverpool Reviews and Implementation Group (LRiG) comments on additional information provided by the manufacturer 26 February 2010
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - AstraZeneca additional information sent in response to the Appraisal Consultation Document
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - AstraZeneca
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - British Thoracic Oncology Group
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - British Thoracic Society
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Department of Health
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Eli Lilly
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Cancer Research UK
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Roy Castle Lung Cancer Foundation
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Royal College of Nursing
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Royal College of Pathologists
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Royal College of Physicians
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Welsh Assembly Government
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - members of the public

This page was last updated: 25 May 2010